




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C09B 47/04, 47/08, C07F 7/18 A61K 31/40	A1	(11) International Publication Number: WO 92/01753 (43) International Publication Date: 6 February 1992 (06.02.92)
(21) International Application Number: PCT/US91/04921 (22) International Filing Date: 12 July 1991 (12.07.91) (30) Priority data: 554,290 17 July 1990 (17.07.90) US (71)(72) Applicants and Inventors: KENNEY, Malcolm, E. [US/US]; 1203 Hereford Road, Cleveland Heights, OH 44118 (US). OLEINICK, Nancy, L. [US/US]; 3727 Meadowbrook Blvd., University Heights, OH 44118 (US). RIHTER, Boris, D. [YU/US]; 2130 Murray Hill Road, Cleveland, OH 44106 (US).		(74) Agents: MINNICH, Richard, J. et al.; Fay, Sharpe, Beall, Fagan, Minnich & McKee, 1100 Superior Avenue, Suite 700, Cleveland, OH 44114-2518 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: PHTHALOCYANINE PHOTSENSITIZERS FOR PHOTODYNAMIC THERAPY AND METHODS FOR THEIR SYNTHESIS AND USE

**(57) Abstract**

The present invention relates to a series of novel phthalocyanine compositions (or compounds) suitable for use as photosensitizers for photodynamic therapy. Specifically, the invention relates to a series of new aluminum (Al) and/or silicon (Si) phthalocyanines having substituted amine or quaternary ammonium axial ligands attached to the central metal, and the use of these new phthalocyanine compositions for the treatment of cancer through photosensitization. Moreover, the present invention is directed to the methods of preparing these compositions for use in photodynamic therapy. The phthalocyanine compounds have formula (I), wherein M = $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$; $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+ \text{I}^-$; $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, or $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+ \text{I}^-$.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU ⁺	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

**PHthalOCYANINE PHOTOSENSITIZERS FOR
PHOTODYNAMIC THERAPY AND METHODS FOR
THEIR SYNTHESIS AND USE**

Background of the Invention

The present invention is directed to a series of novel phthalocyanines suitable for use as photosensitizers for photodynamic therapy. More particularly, the present invention is directed to a series of new aluminum (Al) and silicon (Si) phthalocyanines having substituted amine or quaternary ammonium axial ligands, and the use of these new phthalocyanine compositions for the therapeutic treatment of cancer. In addition, the present invention is directed to the methods of synthesizing these new compositions.

Photodynamic therapy, PDT, is a relatively new process for treating cancer wherein visible light is used to activate a substance, such as a dye or drug, which then attacks, through one or more photochemical reactions, the tumor tissue thereby producing a cell killing, or cytotoxic, effect. It has been discovered that when certain non-toxic photodynamic sensitizers, such as hematoporphyrin derivative ("HpD" or "Photofrin I"), which is extracted from serum and/or components thereof, are applied intravenously, topically, intradermally, etc., to the human or animal body, they are selectively retained by the cancerous tissue while being eliminated by the healthy tissue. As a result, after the administration of a photodynamic substance and the waiting of a certain period of time depending upon the type of photosensitizer utilized (i.e. two to three days after HpD treatment), substantially higher levels of the photosensitizer are retained in the cancerous tissue.

The tumor or cancerous tissue containing the photosensitizer can then be exposed to therapeutic light of an appropriate wavelength and at a specific intensity for activation. The light

-2-

can be directly applied through the skin to the cancerous area from a conventional light source (e.g. laser, sun lamp, white light sources with appropriate filters, etc.), or in cases where the cancerous tissue is located deeper within the body, through surgical or non-surgical entry such as by the use of fiber optic illumination systems, including flexible fiber optic catheters, endoscopic devices, etc. The light energy and the photosensitizer cause a photochemical reaction which kills the cell in which the photosensitizer resides.

10 As a result, by applying a photosensitizer to the animal or human body, waiting for a sufficient period of time for the photosensitizer to permeate throughout the body while dissipating from normal tissue more rapidly than from cancer tissue, and exposing the cancerous region during the sensitive period to
15 suitable light of sufficient intensity, the preferential destruction of the cancerous tissue will occur.

The mechanisms by which the photosensitizers produce their killing effect on the host cells upon illumination by an appropriate light source are not precisely defined and are the
20 subject of continuing research. However, it is thought that there are at least two general mechanisms by which the photosensitizers are chemically altered upon illumination. The first general reaction mechanism involves energy transfer from the excited photosensitizer to oxygen present in the cancerous tissue. The
25 excited photosensitizer transfers its additional energy to the oxygen, producing singlet molecular oxygen (SMO or 1O_2) which consequentially alters essential cell components.

More particularly, in the first general reaction mechanism, it is thought that the light energy causes the photosensitizer to become excited from the ground state, S_0 , to the first excited
30 singlet state, S_1 . The photosensitizer's excited singlet state, S_1 , is then transformed by intramolecular coupling to the lowest lying triplet state T_1 . Through a direct intermolecular process discussed more particularly by John G. Parker of The John Hopkins

-3-

University, Baltimore, Maryland, in U.S. Patent Nos. 4,576,173; 4,592,361; and 4,827,938, the photosensitizer transfers this energy to oxygen molecules present in the tissue and raises them from the ground triplet to the first excited electronic singlet state, $^1\text{O}_2$.

5 The singlet molecular oxygen, $^1\text{O}_2$, destroys or alters vital cellular components such as the cell membrane, etc., ultimately inducing necrosis and destroying the cancerous tissue.

The process by which biological damage occurs as a result of the optical excitation of a photosensitizer in the presence of
10 oxygen is generally referred to as "photodynamic action". A more detailed discussion concerning the use of photodynamic action in the treatment of cancer is discussed by Thomas J. Dougherty, William R. Potter, and Kenneth R. Weishaupt of Health Research, Inc., Buffalo, New York, in a series of patents, i.e. U.S. Patent
15 Nos. 4,649,151; 4,866,168; 4,889,129; and 4,932,934, concerning improved hematoporphyrin and porphyrin derivatives including dihematoporphyrin ether (DHE), the purified form of HpD, and methods utilizing same, for photodynamic therapy.

The second general mechanism thought to be involved in the
20 killing effect produced by certain photosensitizers involves the production of free radicals. Subsequent reactions of the radicals with organic molecules and/or with oxygen results in the biochemical destruction of the diseased tissue.

Although the exact effective mechanisms of the photochemical
25 reactions which produce death of the cancer cells is not clearly understood and varies depending upon the type of photosensitizer utilized, what is clear is that photodynamic therapy is effective for the preferential destruction of cancerous tissue. Furthermore, photodynamic therapy has several attractive features over
30 conventional methods for treating cancer such as chemotherapy, radiation, surgical procedures, etc., in that the photosensitizers utilized are generally non-toxic, concentrate or remain preferentially in cancer cells, can be utilized with other modes of

-4-

treatment since PDT does not interfere with other chemicals or processes, etc.

As a result, photodynamic therapy is now used experimentally for the treatment of malignant diseases in humans and animals. For example, photodynamic therapy has been used successfully for the treatment of a broad range of cancers including metastatic breast tumors, endometrial carcinomas, bladder tumors, malignant melanoma, Kaposi's sarcoma, basal cell carcinoma, chondrosarcoma, squamous cell carcinoma, prostate carcinoma, laryngeal papillomas, mycosis fungoides, superficial cancer of the tracheobronchial tree, cutaneous/mucosal papilloma, gastric cancer, enteric cancer, etc.

The drug in current clinical use is "Photofrin II", a purified version of hematoporphyrin derivative (HpD, or "Photofrin I"). HpD and Photofrin II are complex mixtures of substances and have been the subject of numerous investigations to identify their active compounds. In addition, other porphyrins and porphyrin-like compounds such as chlorins (see U.S. Patent Nos. 4,656,186; 4,693,885; and 4,861,876) and enlarged porphyrins, naphthalocyanines, phthalocyanines, platyrins, porphycenes (see U.S. Patent Nos. 4,649,151 and 4,913,907), purpurins, texaphyrins, and verdins have been investigated as photosensitizers. Numerous other substances, such as "merocyanine 540", xanthenes (Rhodamine 123 6 G&B) cationic cyanic dyes, chalcogenapyrylium dyes, phenothiazinium derivatives, tetracycline, berbine sulphate, acridine orange, and fluorescein have also been used as photosensitizers, however, the porphyrin derivatives are generally preferred because they absorb in the long wave length region (red region) of the visible spectrum.

The specific reactions used by many of the above substances to produce the killing effect in cancer cells on exposure to excitatory light are in most instances not known or well understood. As mentioned above, research continues in this area in order to more fully understand the cytotoxic effects produced by the various photosensitizers.

-5-

Notwithstanding the above, although many of the above identified substances have demonstrated enhanced effects in photodynamic therapy, these substances also produce various side effects which limit their use for photodynamic therapy. The most predominant side effect exhibited by many of the currently utilized substances is the development of uncontrolled photosensitivity reactions in patients after the systemic administration of the photosensitizer and the exposure of the patient to normal sunlight. In this regard, on exposure to the sun, the photodynamic therapy patients can develop generalized skin photosensitization. As a result, the patient after receiving systemic injections of a photosensitizing substance is required to avoid bright light, especially sunlight for periods of about four to eight weeks.

Furthermore, since many of the above photosensitizers bind to other non-cancerous cells, some healthy cell destruction can also occur. Similarly, although many of the photosensitizers are soluble in water, large dosages are required for cellular uptake and/or treatment. Thus, use of many of the above indicated photosensitizers is normally limited to patients with severe cancerous tumors and continuing research is being conducted in order to produce photosensitizing substances, and/or methods of administering such substances, that avoid these side reactions as well as produce enhanced photosensitizing effects.

Considerable attention has recently been directed to a group of compounds having the phthalocyanine ring system. These compounds, called phthalocyanines, are a group of photoactive dyes that are somewhat structurally similar (i.e. have nitrogen containing ring structure) to the porphyrin family. Phthalocyanines are azaporphyrins consisting of four benzoindole nuclei connected by nitrogen bridges in a 16-membered ring of alternating carbon and nitrogen atoms around a central metal atom (i.e. $C_{32}H_{16}N_8M$) which form stable chelates with metal cations. In these compounds, the ring center is occupied by a metal ion (such as a diamagnetic or a paramagnetic ion) that may, depending on the

-6-

ion, carry one or two simple ligands. In addition, the ring periphery may be either unsubstituted or substituted.

Since E. Ben-Hur and I. Rosenthal disclosed the potential use of phthalocyanines as photosensitizers in 1985 (E. Ben-Hur and I. Rosenthal, The phthalocyanines: A new class of mammalian cell photosensitizers with a potential for cancer phototherapy, Int. J. Radiat. Biol. 47, 145-147, 1985), a great deal of research has followed producing a number of phthalocyanines for photodynamic therapy. Although prior studies with phthalocyanines have been generally disappointing, primarily because of the poor solubility characteristics of the basic ring, some of these compounds have attractive characteristics.

For example, unlike some of the porphyrin compounds, phthalocyanines strongly absorb clinically useful red light with absorption peaks falling between about 600 and 810 nm (Abernathy, Chad D., Anderson, Robert E., Kooistra, Kimberly L., and Laws, Edward R., Activity of Phthalocyanine Photosensitizers against Human Glioblastoma in Vitro, Neurosurgery, Vol. 21, No. 4, pp. 468-473, 1987). Although porphyrins absorb light poorly in this wavelength region, as a result of the increased transparency of biological tissues at longer wavelengths, red light is normally used for photodynamic therapy. Thus, the greater absorption of red light by the phthalocyanines over porphyrins indicates deeper potential penetration with the phthalocyanines in photodynamic treatment processes.

Furthermore, it has been found that the addition of certain metal cations (i.e. diamagnetic metal cations such as aluminum) to the phthalocyanine ring will, in some instances, create a fairly stable chelate with enhanced photosensitizing tumoricidal activity. While the mechanisms for producing the photoreactions are not clear (i.e. it is not known whether singlet oxygen or hydroxyl radicals, etc. are produced), the choice of the metal cation is apparently critical in that certain metals (i.e., paramagnetic metals) may

-7-

actually inhibit the phototoxic properties of the resulting compound. Abernathy, et al., pp. 470-471.

In addition, the phthalocyanines offer many benefits over the porphyrin components as photosensitizers in that the phthalocyanines are relatively easy to synthesize, purify, and characterize in contrast to the porphyrins, which are often difficult to prepare. Similarly, the metal phthalocyanines are exceptionally stable compounds in comparison to the porphyrin or porphyrin-like compounds. As a result, certain metallic phthalocyanines, such as aluminum phthalocyanine tetrasulfonate (AlPcS) and chloroaluminum phthalocyanine (AlPcCl), offer a number of advantages over porphyrins as therapeutic agents for photodynamic therapy.

However, notwithstanding some of the benefits indicated above, only a few of the many possible types of ring-substituted phthalocyanines belonging to this group have been examined. By far the most attention has been given to sulfonated phthalocyanines and to phthalocyanines with peripheral substituents carrying hydroxy, alkoxy, and amino substituents. Very little attention has been given to phthalocyanines with complex metal ligands.

The limited variety of phthalocyanines which have been tested vary greatly in their photosensitizing activity. Metal-free phthalocyanines show poor photodynamic activity (Abernathy, C.D., R.E. Anderson, K.L. Kooistra, & E.R. Laws, Jr., "Activity of Phthalocyanine Photosensitizers Against Human Glioblastoma in vitro", Neurosurgery 21, pp. 468-473, 1987; Chan, W.S., J.F. Marshall, G.Y.F. Lam, & I.R. Hart, "Tissue Uptake, Distribution, and Potency of the Photoactivatable Dye Chloroaluminum Sulfonated Phthalocyanine in Mice Bearing Transplantable Tumors", Cancer Res. 48, pp. 3040-3044, 1988; Sonoda, M., C.M. Krishna, & P. Riesz, "The Role of Singlet Oxygen in the Photohemolysis of Red Blood Cells Sensitized by Phthalocyanine Sulfonates", Photochem. Photobiol. 46, pp. 625-632, 1987) as do phthalocyanines containing paramagnetic metals. In contrast, those containing diamagnetic metals, such as

-8-

Al, Sn, and Zn, are active as a result of the long half-life of the triplet state (Chan, W.S., J.F. Marshall, G.Y.F. Lam, & I.R. Hart, "Tissue Uptake, Distribution, and Potency of the Photoactivatable Dye Chloroaluminum Sulfonated Phthalocyanine in Mice Bearing Transplantable Tumors", Cancer Res. 48, pp. 3040-3044, 1988; Sonoda, M., C.M. Krishna, & P. Riesz, "The Role of Singlet Oxygen in the Photohemolysis of Red Blood Cells Sensitized by Phthalocyanine Sulfonates", Photochem. Photobiol. 46, pp. 625-632, 1987). While in general there appears to be an increase in photosensitizing ability with lipophilicity (Berg, K., J.C. Bommer, & J. Moan, "Evaluation of Sulfonated Aluminum Phthalocyanines for use in Photochemotherapy. Cellular Uptake Studies", Cancer Letters 44 pp. 7-15, 1989) some highly lipophilic derivatives, such as a tetraeneopentoxy derivative, are poor photosensitizers (Rosenthal, I., E. Ben-Hur, S. Greenberg, A. Concepcion-Lam, D.M. Drew, & C.C. Leznoff, "The Effect of Substituents on Phthalocyanine Phototoxicity", Photochem. Photobiol. 46, pp. 959-963, 1987).

Recently, Leznoff, et al. (Leznoff, C.C., Vigh, S., Svirskaya, P.I., Greenberg, S., Drew, D.M., Ben-Hur, E. & Rosenthal, I., "Synthesis and Photocytotoxicity of Some New Substituted Phthalocyanines", Photochem. Photobiol. 49, pp. 279-284, 1989) synthesized a series of ring-substituted phthalocyanines. The substituents were hydroxy or alkoxy groups, as well as substituted amines. Of this series, a Zn phthalocyanine with four diethylaminopropyl groups was reported to have some photosensitizing activity against Chinese hamster fibroblast V79 cells in culture. However, it is critical to note that although amine groups were present in the Zn phthalocyanine compound containing the four diethylaminopropyl groups, the amine groups were ring substituents and no simple axial ligands were specified.

For some time the applicants have been searching for phthalocyanines having superior photosensitizing ability. In this search, the applicants have emphasized compounds with complex metal ligands. Initially, applicants examined the photocytotoxicity of

-9-


twenty-one phthalocyanines taken from a collection in the applicants' laboratories to Chinese hamster fibroblasts, i.e. V79 cells. One of these phthalocyanines was $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{OCH}_2\text{-CHOHCH}_2\text{N}(\text{C}_2\text{H}_5)_2$, a phthalocyanine composition carrying a hydroxyl amine functional group. This was found to be taken up efficiently by the Chinese hamster fibroblast V79 cells and to have excellent photocytotoxicity. However, solutions of this composition in dimethylformamide were found to decompose relatively rapidly. Further, it appeared that the composition might have dark toxicity (i.e. be toxic to tissues in the absence of light) in vivo because of its $\text{-OCHOHCH}_2\text{NR}_2$ functional group.

With the results of this preliminary work in mind, the applicants then prepared and studied a series of new aluminum and silicon phthalocyanines having relatively simple ligands carrying NR_2 or NR_3^+ functions. The present invention is the result of applicants' studies of these compounds, and the use of the same for photodynamic therapy.

Summary of the Invention

In one aspect, the present invention is directed to a series of phthalocyanine compounds (or compositions) with modifying moieties linked to the central metal, which is either aluminum (Al) or silicon (Si). Specifically, the present invention relates to a series of aluminum or silicon phthalocyanines having an axial group, or groups, carrying, or terminating in, an amine or quaternary ammonium function. The specific embodiments of the invention can be generally characterized by the following Formula I:

-10-



(I)

wherein: m = $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$;
 $\text{CH}_3\text{SiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 5 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$; or
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$.

In an additional aspect, the present invention relates to the various methods of synthesizing the novel phthalocyanine compositions. The novel phthalocyanines produced by the invention exhibit enhanced characteristics which make them well suited for photodynamic therapy when utilized alone or in combination with a pharmaceutical carrier.

In a further aspect, the present invention is directed to various methods for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of a phthalocyanine composition having an axial group, or groups, carrying, or terminating in an amine or quaternary ammonium function, and applying light of sufficient wavelength and intensity to activate the composition thereby exerting a cell killing, or cytotoxic, effect on the cancer tissue.

-11-

Brief Description of the Drawings

The following is a brief description of the drawings which are presented for the purpose of illustrating the invention and not for the purpose of limiting same.

5 FIGURE 1 is a graph illustrating the photodynamic efficacy of the various compositions of the present invention in comparison to AlPcCl. The phthalocyanine composition compounds of the present invention were tested for their photodynamic efficiency against Chinese hamster fibroblast V79 cells by colony formation.
10 Monolayer cultures were treated with the indicated phthalocyanine composition for 18 hours, irradiated with various fluences of red light, and immediately trypsinized and replated at appropriate aliquots in triplicate. Colonies of at least 50 cells were counted after 7-10 days. The plating efficiency of the untreated cells was
15 approximately 90%.

FIGURE 2 is a graph demonstrating the percent survival of the compositions of the present invention in comparison to AlPcCl in relation to intracellular phthalocyanine (nmoles/ 10^7 cells) and light fluence (kJ/m^2). In this regard, in FIGURE 2 the data of
20 FIGURE 1 were replotted as a function of the product of the amount of cell-associated phthalocyanine and the light fluence.

Detailed Description of the Invention

The present invention relates to a series of novel phthalocyanine compositions (or compounds) suitable for use as
25 photosensitizers for photodynamic therapy. Specifically, the invention relates to a series of new aluminum (Al) and/or silicon (Si) phthalocyanines having substituted amine or quaternary ammonium axial ligands attached to the central metal, and the use
30 of these new phthalocyanine compositions for the treatment of cancer through photosensitization. Moreover, the present invention

-12-

is directed to the methods of preparing these compositions for use in photodynamic therapy.

Although research has recently been directed to the use of various phthalocyanines for photodynamic therapy, this activity has been principally directed to phthalocyanines with peripheral substituents, and little, if any, attention has been given to phthalocyanines with complex metal ligands. Along this line, in the phthalocyanine compositions described in the prior art, only simple ligands, such as Cl or OH ligands, are attached to the central metal. However, in the new compositions of the present invention, axial ligands carrying or, terminating in an amine function or a quaternary ammonium function are attached to the central metal. As a result, it is believed by the applicants that these more complex axial ligands give the new phthalocyanine compositions the potential to bind to the various species that assist in transporting the composition to and from their targets, as well as enhance the potential for the phthalocyanines to bind to their specific target cells.

This is demonstrated in that some of the novel phthalocyanines of the present invention having substituted amine or quaternary ammonium axial ligands attached to either aluminum or silicon as the central metal, are much more effective in producing photodynamic activity when compared with chloroaluminum phthalocyanine (AlPcCl). The enhanced cytotoxic effects produced are due to the increased cellular uptake of the compositions and/or the increased loss of clonogenicity as a function both of the concentration of the phthalocyanine and the red light fluence.

More particularly, in applicants' investigation for phthalocyanines exhibiting enhanced photosensitizing ability through the synthesis and evaluation of a number of phthalocyanine compositions having complex metal ligands, the applicants have produced a series of new aluminum and silicon phthalocyanines having substituted amine or quaternary ammonium axial ligands. In this regard, two silicon phthalocyanines and one aluminum

-13-


phthalocyanine with axial groups terminating in an amine function were prepared:

$\text{SiPc}(\text{CH}_3)(\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2)$, $\text{SiPc}(\text{OH})(\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2)$, and $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$. In addition, two silicon phthalocyanines

5 and one aluminum phthalocyanine with axial groups terminating in a quaternary ammonium function were prepared:

$\text{SiPc}(\text{OH})(\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-)$, $\text{SiPc}(\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-)_2$, and $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$.

The new phthalocyanine compositions can be generally
10 characterized by the following formula:



wherein: $m =$ $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$;
 $\text{CH}_3\text{SiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
15 $\text{HOSiSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$; or
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$.

The new phthalocyanine compositions bearing the substituted amine or quaternary ammonium axial ligands have been evaluated for their photodynamic efficiency against Chinese hamster fibroblast
20 V79 cells in vitro. Chloroaluminum phthalocyanine (AlPcCl) was used as a reference compound. Along this line, the compounds, $\text{SiPc}(\text{CH}_3)\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ and $\text{SiPc}(\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-)_2$, were found to be inactive as photosensitizers owing to poor cellular uptake. The most efficient photosensitizer, as judged by

-14-

uptake, growth delay, and photocytotoxicity, was $\text{SiPc}(\text{OH})\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$. The related quaternary ammonium compound, $\text{SiPc}(\text{OH})\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$, displayed poorer uptake but induced marked photocytotoxicity. When expressed as a function of the product of intracellular phthalocyanine and the fluence reducing cell survival to 10%, this quaternary ammonium compound was the most efficient photosensitizer.

The specific process utilized to synthesize the aluminum and silicon phthalocyanine compounds of the present invention, and the enhanced results produced through the use of these new compounds for photodynamic therapy, are more particularly described below in the following example.

EXAMPLE 1

Synthesis of Phthalocyanines

15 $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ - Under argon gas a solution of CH_3MgCl in tetrahydrofuran (3.0 M, 45 mL) was added dropwise to a cool (ice bath) solution of $(\text{CH}_3\text{O})_3\text{Si}(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (11 mL) in tetrahydrofuran (100 mL), and the resulting suspension was stirred for 2 hours while being kept cool ($\sim 5^\circ\text{C}$). Methanol (20 mL) then was added to the suspension and the mixture formed was filtered. The solid was washed with ether (50 mL) and the washings and filtrate were combined and concentrated with a rotary evaporator (45°C). The concentrate was fractionally distilled under vacuum (45 torr) and a selected fraction ($86-88^\circ\text{C}$, 5.0 g.) was retained (55%): NMR (25 CDCl_3) δ 3.42 (s, CH_3O), 2.24 (m, $\gamma\text{-CH}_2$), 2.20 (s, NCH_3), 1.49 (m, $\beta\text{-CH}_2$), 0.57 (m, $\alpha\text{-CH}_2$), 0.10 (s, CH_3Si).

The compound is a colorless liquid.

$\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ - Compound I. A mixture of $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (203 mg) produced above and a suspension of 30 $\text{AlPcOH}\cdot x\text{H}_2\text{O}$ (56 mg) and 2-ethylpyridine (15 mL) that had been dried by distillation (3 mL of distillate) was refluxed for 45 minutes

-15-

and filtered. The filtrate was evaporated to dryness with a rotary evaporator (~40°C) and the solid was dissolved CH_2Cl_2 (2mL). Hexanes (3 mL) were added to the solution and the resulting suspension was filtered. The solid was washed (benzene and hexanes), vacuum dried (65°C), and weighed (63 mg, 98% assuming $\text{AlPcOH} \cdot 3\text{H}_2\text{O}$); NMR ($\text{C}_5\text{D}_5\text{N}$, 70°C) δ 9.65 (m, 1,4-PcH), 8.28 (m, 2,3-PcH), 1.63 (s, NCH_3), 0.99 (m, $\gamma\text{-CH}_2$), -0.50 (m, $\beta\text{-CH}_2$), -1.80 (m, $\alpha\text{-CH}_2$), -2.33 (s, SiCH_3).

The compound is blue and is soluble in CH_2Cl_2 and toluene.

10 $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$ - Compound II. A mixture of $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (30 mg), benzene (10 mL), and CH_3I (15 μL) was refluxed for 1.5 hours, cooled, and filtered. The solid was vacuum dried (60°C) and weighed (31 mg, 86%); NMR ($\text{C}_5\text{D}_5\text{N}$, 70°C) δ 9.75 (m, 1,4-PcH), 8.34 (m, 2,3-PcH), 2.90 (s, NCH_3), 2.02 (m, $\gamma\text{-CH}_2$), -0.53 (m, $\beta\text{-CH}_2$), -1.87 (m, $\alpha\text{-CH}_2$), -2.40 (s, SiCH_3).

15 The compound is a blue solid and is soluble in CH_2Cl_2 and CH_3OH but is insoluble in toluene and H_2O .

$\text{CH}_3\text{SiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ - Compound III. Procedures in this synthesis that were carried out under low light conditions (room lights off, shades drawn) are identified by the symbol 1. A mixture of $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (224 mg) and a suspension of CH_3SiPcOH (117 mg) and pyridine (25 mL) that had been dried by distillation (1) was slowly distilled (1) for 3 hours (10 mL of distillate) and then filtered (1, no solid). The filtrate was 25 evaporated to dryness with a rotary evaporator (1, 75°C), and the solid was dissolved in CH_2Cl_2 (1, 2 mL). Hexanes (30 mL) were added to the solution (1) and the resulting suspension was filtered (1). The solid was washed (hexanes), vacuum dried (65°C), and weighed (11 mg, 76%); mp > 260°C; NMR (CDCl_3) δ 9.63 (m, 1,4-PcH), 8.33 (m, 2,3-PcH), 1.74 (s, NCH_3), 1.01 (m, $\gamma\text{-CH}_2$), -1.18 (m, $\beta\text{-CH}_2$), -2.25 (m, $\alpha\text{-CH}_2$), -2.96 (s, $\text{Si}(\text{CH}_3)_2$), -6.35 (s, SiCH_3).

-16-

The compound is dark green and is soluble in CH_2Cl_2 and toluene. Solutions of it are rapidly photolyzed by white light.

$\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ - Compound IV. A mixture of $\text{CH}_3\text{SiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (35 mg), $\text{N}(\text{C}_2\text{H}_5)_3$ saturated with H_2O (0.2 mL), and toluene (70 mL) was irradiated with an incandescent light (300 W in 35 mm slide projector) for 15 minutes. The resulting suspension was concentrated with a rotary evaporator ($\sim 45^\circ\text{C}$) and the concentrate (~ 5 mL) was diluted with hexanes (1 mL). The suspension formed was filtered and the solid was washed (hexanes), vacuum dried (65°C), and weighed (33 mg, 96%): mp $> 260^\circ\text{C}$; NMR (dimethylformamide- d_7 , 70°C) δ 9.68 (m, 1,4-PcH), 8.47 (m, 2,3-PcH), 1.52 (s, NCH_3), 0.74 (m, $\gamma\text{-CH}_2$), -1.11 (m, $\beta\text{-CH}_2$), -2.27 (m, $\alpha\text{-CH}_2$), -2.89 (s, SiCH_3). MS-HRFAB exact mass m/z calculated for $\text{C}_{39}\text{H}_{35}\text{N}_9\text{O}_2\text{Si}_2$ M^+ 717.2452. Found 717.2422.

The compound is blue and is soluble in CH_2Cl_2 and toluene.

$\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$ - Compound V. A mixture of $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (24 mg), CH_3I (25 μL), and benzene (10 mL) was refluxed for 1.5 hours, cooled, and filtered. The solid was washed (benzene), vacuum dried (65°C), and weighed (23 mg, 81%): NMR (dimethylformamide- d_7 , 70°C) δ 9.66 (m, 1,4-PcH), 8.45 (m, 2,3-PcH), 2.87 (s, NCH_3), 2.06 (m, $\gamma\text{-CH}_2$), -0.97 (m, $\beta\text{-CH}_2$), -2.25 (m, $\alpha\text{-CH}_2$), -2.83 (s, SiCH_3). MS-HRFAB exact mass m/z calculated for $\text{C}_{40}\text{H}_{38}\text{N}_9\text{O}_2\text{Si}_2$ $(M\text{-I})^+$ 732.2687. Found 732.2668.

The compound is blue. It is soluble in CH_2Cl_2 and CH_3OH but is insoluble in toluene and H_2O .

$\text{SiPc[OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$. A mixture of $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ (239 mg) and a suspension of $\text{SiPc}(\text{OH})_2$ (232 mg) and 2-ethylpyridine (30 mL) that had been dried by distillation (~ 2 mL of distillate) was slowly distilled for 2 hours (~ 5 mL of distillate). The resulting solution was filtered, the filtrate was evaporated to dryness with a rotary evaporator ($\sim 60^\circ\text{C}$), and the

-17-

solid was dissolved in CH_2Cl_2 (3.5 mL). The CH_2Cl_2 solution was diluted with hexanes (~40 mL), the suspension formed was filtered, and the solid was washed (hexanes), air dried, and weighed (263 mg, 76%); NMR (CDCl_3), δ 9.63 (m, 1,4-PcH), 8.34 (m, 2,3-PcH), 1.65 (s, NCH_3), 0.90 (m, $\gamma\text{-CH}_2$), -1.10 (m, $\beta\text{-CH}_2$), -2.26 (m, $\alpha\text{-CH}_2$), -2.87 (s, SiCH_3).

The compound is blue and is soluble in CH_2Cl_2 and toluene.

$\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$ - Compound VI. A mixture of $\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$ produced above (30 mg), CH_3I (36 μL), and benzene (5 mL) was refluxed for 1.5 hours, cooled, and filtered. The solid was washed (benzene, hexanes), vacuum dried (60°C), and weighed (32 mg, 79%): NMR (CD_3OD) δ 9.63 (m, 1,4-PcH), 8.41 (m, 2,3-PcH), 1.65 (s, NCH_3), 0.90 (m, $\gamma\text{-CH}_2$), -1.10 (m, $\beta\text{-CH}_2$), -2.21 (m, $\alpha\text{-CH}_2$), -2.90 (m, SiCH_3).

The compound is blue and is soluble in CH_2Cl_2 and CH_3OH but is insoluble in toluene. It disperses in H_2O but does not dissolve in it.

Cell Culture

Chinese hamster V79-379 lung fibroblasts were grown in monolayer culture in McCoy's 5A medium (Gibco Laboratories, Grand Island, NY) augmented with 10% calf serum and buffered with 20 mM HEPES (pH 7.4).

Uptake of Phthalocyanines

Total uptake was determined by scraping the phthalocyanine-treated monolayer, collecting the cells on a glass-fiber filter, and extracting the phthalocyanine in ethanol, as previously described by Ramakrishnan, et al., 1989. (Ramakrishnan, N., M.E. Clay, M.F. Horng, A.R. Antunez, & H.H. Evans, "DNA Lesions and DNA Degradation in Mouse Lymphoma L5178Y Cells After Photodynamic Treatment Sensitized by Chloroaluminum Phthalocyanine", Photochem. Photobiol., in press, 1989). The amount of drug was determined by

-18-

absorption at 674 nm and expressed relative to the number of cells, as measured in a Coulter cell counter on an aliquot of the cell population. Controls included cells not treated with drug, medium alone, and drug-containing medium without cells. The results of the total uptake of the various compositions of the present invention in comparison to AlPcCl are set forth below in Table 1.

Drug Treatment and Light Exposure

The cells were treated with 1 μM AlPcCl (from Eastman Kodak, Rochester, NY) or with phthalocyanine compositions I-VI (0.5-1.0 μM final concentration in the medium) for 18 hours by adding the appropriate volume of a 1.0 mM stock solution in dimethylformamide (DMF) to the culture medium. The growth medium was replaced with 4 ml Hank's balanced salt solution (HBSS), and the cells were irradiated. The light source was a 500 W tungsten-halogen lamp located approximately 29 inches below the surface of a glass exposure tray. The visible light administered to the cells was filtered to allow passage of only that portion of the visible spectrum above 600 nm (Lee Primary red filter No. 106, Vincent Lighting, Cleveland, Ohio). The fluence rate was approximately 0.074 kJ/m²/s at the level of the cell monolayer.

Growth Delay

At the time of light exposure, there were approximately 1.5×10^5 cells per 25 cm² flask. Following irradiation, the HBSS was replaced by 10 ml of fresh complete growth medium, and the cultures were returned to the 37°C incubator. At various times before and after irradiation, duplicate cultures were trypsinized and counted. Controls included untreated cells and cells treated with light alone or drug alone. In addition, in each experiment, the drug to be tested was compared to a standard treatment, i.e. 1 μM AlPcCl for 18 hours followed by 12 kJ/m² light. The results of the growth delay analysis for each of the compositions I-VI in comparison to AlPcCl are set forth in Table 1 below.

-19-

Clonogenic cell survival

Cells were irradiated at a density of approximately 2×10^6 per 25 cm² flask. Immediately after irradiation, the cell monolayer was treated with trypsin, and appropriate aliquots were
5 plated in triplicate to give 100 to 200 colonies in each 10-cm Petri dish. Cell survival was determined by the ability of the cells to form colonies containing at least 50 cells. The response of cells treated with 1 μ M AlPcCl and light was compared in each experiment.

-20-

TABLE 1Activities of Several Al and Si Phthalocyanines

Compound No.	Structure	Concn. (μ M)	Efficacy Relative to 1 μ M(AlPcCl)			
			Uptake	Growth Delay (12 kJ/m ²)	$\frac{F_{10}(\text{AlPcCl})}{F_{10}(\text{Pc})}$	$\frac{CF_{10}(\text{AlPcCl})}{CF_{10}(\text{Pc})}$
	AlPcCl	1.0	1.0	1.0	1.0	1.0
I.	AlPcOSi(CH ₃) ₂ (CH ₂) ₃ N(CH ₃) ₂	1.0	2.3	2.1	0.94	0.51
II.	AlPcOSi(CH ₃) ₂ (CH ₂) ₃ N(CH ₃) ₃ ⁺ I ⁻	1.0	1.8	3.4	0.99	0.72
III.	CH ₃ SiPcOSi(CH ₃) ₂ (CH ₂) ₃ N(CH ₃) ₂	1.0	0.07	0.05	ND	ND
IV.	HOSiPcOSi(CH ₃) ₂ (CH ₂) ₃ N(CH ₃) ₂	0.5	1.3	>3	1.85	3.9
		1.0	1.64	ND	4.25	3.5
V.	HOSiPcOSi(CH ₃) ₂ (CH ₂) ₃ N(CH ₃) ₃ ⁺ I ⁻	1.0	0.3	0	0.59	3.0
VI.	SiPc(OSi(CH ₃) ₂ (CH ₂) ₃ N(CH ₃) ₃ ⁺ I ⁻) ₂	1.0	0.1	0.05	ND	ND

-21-

Results

All of the compounds have been examined for the extent of cellular uptake after exposure of V79 cells to 1 μM or less in complete medium, and the data of Table 1 are presented relative to the uptake from 1 μM AlPcCl, which was 0.723 ± 0.172 nmole/ 10^7 cells (mean \pm S.D., 25 determinations). Compounds I, II, and IV were taken up into the cells more efficiently than was AlPcCl under these conditions. In particular, when the concentration of compound IV was 1 μM in the medium, the uptake into the cells was sufficiently high that some of the uptake and phototoxicity studies were repeated at 0.5 μM . Compounds III, V, and VI were poorly incorporated into V79 cells.

Photodynamic action against V79 cells was assessed both by measurement of growth delay and by assay of the loss of clonogenicity. With both assays, none of the compounds showed any dark toxicity at concentrations of 1.0 μM or less for up to 18 hours.

The inhibition of V79 culture growth was measured during a three day period following red light irradiation (12 kJ/m^2) of phthalocyanine-pretreated cells. With each of the active compounds, as well as with AlPcCl, there was an initial decrease in cell density, as dead cells became detached from the monolayer. Thereafter, the cell number per flask increased, as living cells grew and divided. The time for the cell density to recover to the level at the time of light exposure was considered the growth delay. Cells treated with 1 μM AlPcCl for 18 hours and 12 kJ/m^2 light were used for comparison purposes in each experiment and demonstrated a growth delay of approximately 24 hours. The ratio of the growth delay for the test photosensitizer and the growth delay for AlPcCl measured in the same experiment is recorded in Table 1. There was little or no inhibition of culture growth when cells were exposed to compounds III, V, or VI as expected from the poor cellular uptake of these drugs. In contrast, substantial

-22-

inhibition was observed for compounds I, II, and IV. A value of >3 for compound IV (Table 1) indicates that the cell density had not recovered to the initial level during the three day observation period.

5 Photocytotoxicity of the new phthalocyanines was also assessed by clonogenic assay (Table 1, Figure 1). In all experiments, $1 \mu\text{M}$ AlPcCl was included for comparison purposes. From the survival curves (Figure 1), the fluence reducing the cell survival to 10% (F_{10}) was obtained. The ratio of the F_{10} for AlPcCl and the F_{10} for
10 the test compound is recorded in Table 1. Compounds I and II appear to be nearly as efficient photosensitizers as AlPcCl, while compound IV (assayed at half the concentration) was almost twice as efficient as the standard AlPcCl. Clonogenic assays were not conducted for compounds III and VI, since the data on uptake and
15 growth delay suggested that these compounds would have poor activity. However, in spite of the low efficiency of compound V in inhibiting cell growth, survival measurements were made for this compound, because it was taken up into V79 cells somewhat more efficiently than compounds III and VI.

20 In order to take differences in cellular uptake into consideration in the assessment of the relative efficiency of these phthalocyanines as photosensitizers of V79 cells, the survival data were replotted against the product of intracellular phthalocyanine concentration and light fluence (Figure 2). From these curves, the
25 product of intracellular concentration and light fluence reducing survival to 10% (CF_{10}) was obtained, and comparisons of the values for AlPcCl and the test compounds are recorded in Table 1. By this and the other criteria, compound IV appears to be the most efficient photosensitizer. However, when consideration is given to
30 the lesser cell uptake of compound V, it appears to be about as strong a photosensitizer as compound IV.

-23-

Discussion

Photocytotoxicity

The low activity of compounds III and VI appears to be due to poor cell uptake. Both of these compounds have functional groups on both faces of the phthalocyanine ring, and it is possible that one face of the ring must be free for proper interaction with target biomolecules. Either Si phthalocyanine with no more than a hydroxyl group on one face (IV) or Al phthalocyanine with one face free of substituents (I and II) allows efficient cellular uptake as well as a high degree of cellular inactivation. Thus, both tertiary and quaternary amines appear to be efficacious structures. Compound V is an anomaly. Although it has features on either face of the phthalocyanine ring found on active molecules, the combination appears not to allow efficient cellular uptake. However, that which is incorporated into the cells has good photodynamic activity.

The results of the in vitro biological tests of the new phthalocyanines are an important introduction to the design of a new class of photosensitizers. The results suggest that tertiary and quaternary amines may be an important class of structures to be explored. The axial ligands of the series of compounds listed in Table 1 are simpler than the corresponding ligand of the original diethylamine which served as a prototype. The simpler ligands appear to have the advantages of stability in solution, making them easier to study. The instability of the diethylamine precluded precise measurements of the concentration of the active species at the time of irradiation. Therefore, the true photosensitizing activity of the prototype compound may also be high.

The invention has been described with reference to the preferred embodiment. Obviously, modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is intended that the invention be construed as including all such modifications and alterations

-24-

insofar as they come within the scope of the appended claims or the equivalents thereof.

In addition, although the present invention has been described with reference to the effectiveness of the phthalocyanine compositions in photodynamic therapy for the destruction of cancer tissue, it is well understood by those skilled in the art that the compositions of the invention may be well suited for other therapeutic purposes. Along this line, it is contemplated that other possible uses of the composition of the present invention include:


- (1) the purging of bone marrow for autologous bone marrow transplantation;
- (2) the purging of viruses from whole blood or blood components;
- 15 (3) the treatment of psoriasis;
- (4) the treatment of warts;
- (5) the treatment of macular degeneration; and
- (6) the treatment of intra-arterial plaques.

Thus, the new phthalocyanine compositions of the present invention may be effective for a wide variety of therapeutic uses.

-25-

Having thus described the preferred embodiment, the invention is now claimed to be:

1. A phthalocyanine composition of Formula I:



(I)

wherein: $m =$ $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$;
 $\text{CH}_3\text{SiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$; or
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$.

2. A therapeutic composition comprising the phthalocyanine composition according to claim 1 and a pharmaceutical carrier therefor.

3. A method for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of the phthalocyanine composition according to claim 1, and applying light of sufficient wave length and intensity to activate said composition, whereby said activated composition exerts a cytotoxic effect on said cancer tissue.

-26-

4. The method of claim 3, wherein said light is of the visible spectrum above 600 nm.

5. A method for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of a phthalocyanine composition selected from the group consisting of $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$, and $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, and applying light of sufficient wave length and intensity to activate said composition, whereby said activated composition exerts a cell killing effect on said cancer tissue.

6. The method of claim 5, wherein said light is of the visible spectrum above 600 nm.

7. A method for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of a phthalocyanine composition having an axial group carrying an amine function, and applying light of sufficient wave length and intensity to activate said composition, whereby said activated composition exerts a cell killing effect on said cancer tissue.

8. The method of claim 7, wherein said light is of the visible spectrum above 600 nm.

9. A method for destroying cancer tissue comprising the steps of administering to the cancer cells an effective amount of a phthalocyanine composition having an axial group carrying a quaternary ammonium function, and applying light of sufficient wave length and intensity to activate said composition, whereby said activated composition exerts a cell killing effect on said cancer tissue.

-27-

10. The method of claim 9, wherein said light is of the visible spectrum above 600 nm.

11. A method for synthesizing $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ comprising the steps of:

a) adding a solution of Grignard reagent comprised of CH_3MgCl in an ether, wherein $x = \text{Cl}, \text{Br}, \text{or I}$, to a cooled solution of $(\text{CH}_3\text{O})_3\text{Si}(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ in an ether;

b) destroying the excess Grignard reagent with a proton donor; and,

c) isolating the product from the reaction mixture by distillation.

12. The synthesized $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ produced by the process of claim 11.

13. A method for synthesizing $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ comprising the steps of:

a) treating a suspension of $\text{AlPcOH} \cdot x\text{H}_2\text{O}$ and 2-ethylpyridine with $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ at an elevated temperature; and,

b) recovering the product from the reaction mixture by the evaporation of the mixture.

14. The synthesized $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ produced by the process of claim 13.

15. A method for synthesizing $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$ comprising the steps of:

a) refluxing a mixture of $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, benzene and CH_3I ; and,

b) recovering the reaction product by the filtration of the reaction mixture.

-28-

16. The synthesized $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$ produced by the process of claim 15.

17. A method for synthesizing $\text{CH}_3\text{SiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ comprising the steps of:

- a) distilling under conditions of low light a mixture of $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ and a suspension of CH_3SiPcOH and pyridine;
- b) recovering the reaction product by evaporating the reaction mixture.

18. The synthesized $\text{CH}_3\text{SiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ produced by the process of claim 17.

19. A method for synthesizing $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ comprising the steps of:

- a) irradiating a mixture of $\text{CH}_3\text{SiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, $\text{N}(\text{C}_2\text{H}_5)_3$ saturated with H_2O , and toluene to produce a suspension; and,
- b) recovering the reaction product by precipitating the reaction product from the reaction mixture with a solvent.

20. The synthesized $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ produced by the process of claim 19.

21. A method for synthesizing $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$ comprising the steps of:

- a) refluxing a mixture of $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, CH_3I and benzene; and,
- b) recovering the reaction product by filtering the reaction mixture.

22. The $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$ synthesized by the process of claim 21.

-29-

23. A method for synthesizing $\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$ comprising the steps of:

- a) distilling a mixture of $\text{CH}_3\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$ and a suspension of $\text{SiPc}(\text{OH})_2$ and 2-ethylpyridine; and,
- b) recovering the reaction product by evaporating the reaction mixture.

24. The $\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$ synthesized by the process of claim 23.

25. A method for synthesizing $\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$ comprising the steps of:

- a) refluxing a mixture of $\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]_2$, CH_3I and benzene; and,
- b) recovering the reaction product by filtering the reaction mixture.


26. The $\text{SiPc}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$ synthesized by the process of claim 25.

AMENDED CLAIMS

[received by the International Bureau on 20 December 1991 (20.12.91);
original claims 1-3 and 5 amended; other claims unchanged (2 pages)]

Having thus described the preferred embodiment, the invention is now claimed to be:

1. A phthalocyanine composition of Formula I:



(I)

wherein: M = $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{AlOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$;
 $\text{CH}_3\text{SiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$;
 $\text{HOSiOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$; or
 $\text{Si}[\text{OSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-]_2$.

2. A therapeutic composition comprising the phthalocyanine compound according to claim 1 and a pharmaceutical carrier therefor.

3. A method for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of the phthalocyanine compound according to claim 1, and applying light of sufficient wave length and intensity to activate said compound, whereby said activated compound exerts a cytotoxic effect on said cancer tissue.

4. The method of claim 3, wherein said light is of the visible spectrum above 600 nm.

5. A method for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of a phthalocyanine compound selected from the group consisting of $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, $\text{AlPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$, and $\text{HOSiPcOSi}(\text{CH}_3)_2(\text{CH}_2)_3\text{N}(\text{CH}_3)_3^+\text{I}^-$, and applying light of sufficient wave length and intensity to activate said compound, whereby said activated compound exerts a cell killing effect on said cancer tissue.


6. The method of claim 5, wherein said light is of the visible spectrum above 600 nm.

7. A method for destroying cancer tissue comprising the steps of administering to the cancer tissue an effective amount of a phthalocyanine composition having an axial group carrying an amine function, and applying light of sufficient wave length and intensity to activate said composition, whereby said activated composition exerts a cell killing effect on said cancer tissue.

8. The method of claim 7, wherein said light is of the visible spectrum above 600 nm.


9. A method for destroying cancer tissue comprising the steps of administering to the cancer cells an effective amount of a phthalocyanine composition having an axial group carrying a quaternary ammonium function, and applying light of sufficient wave length and intensity to activate said composition, whereby said activated composition exerts a cell killing effect on said cancer tissue.

1/2



SUBSTITUTE SHEET

2/2



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US91/04921**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

US. -540/128,135; 514/183; 556/413

IPC(5): C09B 47/04,08; C07F 7/18; A61K 31/40

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

U.S. 540/128,135; 514/183; 556/413
IPC(5) A61K 31/40

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

STN-Chemical Abstract Service-structure Search
APS-USPTO Automated Patent Searching.

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
A	US, A, 3,094,536 (KENNEY ET AL.) 18 JUNE 1963 See figs. 1-7	1-10,13-14, 16-20,22-24,26
A	Journal of the American Chemical Society, vol. 97, No. 11, May 28 1975, Mooney et al., "Determination of the Si _{PC} -O-Si _{me} Bond Angle Common to the Shift Reagent Compounds (CH ₃) ₃ SiO(PCSiO)-Si(CH ₃) ₃ (x=1-5) by an Induced Shift Technique and Determination of the structure of PCSi[OSi(CH ₃) ₃] ₂ by X-Ray Crystall- ography", pages 3033-3038.	1-10,13-14, 16-20,22-24,26
A	Inorganic Chemistry, vol. 90, 1970, Kane et al. "The Nuclear Magnetic Resonance Spectra and the Electronic Spectra of some silicon and Germanium Phthalocyanines", pages 1445-1448.	1-10,13-14, 16-20,22-24,26
A	Inorganic Chemistry, vol. 5, no. 11, November 1966 Esposito et al., "The Synthesis and Physical Propert- ies of Some Organo-and Organosiloxy-silicon Phthalocy- anines", pages 1979-1984.	1-10,13-14, 16-10,22-24,26

* Special categories of cited documents: **

"A" document defining the general state of the art which is not
considered to be of particular relevance

"E" earlier document but published on or after the international
filing date

"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or
other means

"P" document published prior to the international filing date but
later than the priority date claimed

"T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

"X" document of particular relevance: the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step

"Y" document of particular relevance: the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

18 OCTOBER 1991

01 NOV 1991

International Searching Authority

Signature of Authorized Officer

ISA/US

PHILLIP I. DATLOW

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

X	Morrison and Boyd, "Organic Chemistry", 4th ed., 1983, Allyn and Bacon, Inc. (Boston), page 919.	15,21,25
$\frac{A}{X}$	Chemical Abstracts, vol. 110, no. 240159s, issued 1989, (EP 293,009 Kobayashi, 30 November 1988)	$\frac{11}{12}$
$\frac{A}{X}$	Chemical Abstracts, vol. 62, no. 10628a, issued 1965, (Netherlands, 6,402,923, 11 November 1964)	$\frac{11}{12}$

V ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

- 1 ☐ Claim numbers _____, because they relate to subject matter^{1,2} not required to be searched by this Authority, namely:
- 2 ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out^{1,3}, specifically:
- 3 ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

See attached sheet

- 1 ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
- 2 ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
- 3 ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
- 4 ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

CONTINUATION SHEET

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

- I. Claims 1-10,14,16,18,20,22,24 and 26 drawn to phthalocyanine derivatives, compositions and method for destroying cancer tissue, classified in class 540, subclass 128.
- II. Claim 11, drawn to a method for synthesizing a silyl amine intermediate, classified in class 556, subclass 413.
- III. Claim 12, drawn to a silyl amine intermediate, classified in class 556, subclass 413.
- IV. Claims 13,17 and 23, drawn to a method for synthesizing phthalocyanines of Group I by reacting metal phthalocyanine hydroxides with a pyridine and a silyl amine, classified in class 540, subclass 128.
- V. Claims 15,21 and 25, drawn to a method for synthesizing phthalocyanines of Group I by refluxing metal phthalocyanine amine with benzene and methyl iodide, classified in class 540, subclass 128.
- VI. Claim 19, drawn to a method for synthesizing phthalocyanines of Group I by irradiating metal-phthalocyanine amines, triethylamine and toluene in water, classified in class 540, subclass 128. The inventions listed as Groups [I and II] do not meet the requirements for Unity of Invention for the following reasons [the intermediate of Group III has a separate utility than to make the compounds of Group I such as to make structurally diverse amino compounds. Also, the compounds of Group I and III are patentably distrust.] The inventions listed as Groups [I,IV,V, and VI] do not meet the requirements for Unity of Invention for the following reasons: [Groups IV-VI demonstrate that multiple, patentably distinct processes can be used to make the compounds of Group I.] The inventions listed as Groups [II,III] do not meet the requirements for Unity of Invention for the following reasons: [The product of Group III can be made by a materially different process than that required by Group II, such as by aminoalkylation.]